Literature DB >> 3885712

Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens.

J C Jennette, C G Hipp.   

Abstract

The frequency, distribution, and intensity of C1q localization were evaluated in 800 renal biopsy specimens, and these observations were correlated with light, immunofluorescence, and electron microscopy findings. Intense C1q immunostaining was most frequent in proliferative and membranous lupus glomerulonephritis and in a recently described form of proliferative glomerulonephritis designated "C1q nephropathy." Moderate intensity C1q immunostaining was observed in most cases of type I but not type II, membranoproliferative glomerulonephritis. Unlike lupus membranous glomerulopathy, non-lupus membranous glomerulopathy usually did not have extensive C1q localization. C1q was scanty or absent in IgA nephropathy and antiglomerular basement membrane antibody mediated glomerulonephritis. C1q, along with IgM and C3, was often present at sites of glomerular sclerosis, especially in focal segmental glomerulosclerosis. Extraglomerular C1q was most frequent and most intense in cases of lupus nephritis having extraglomerular immune deposits. The presence or absence and intensity of C1q immunostaining were shown to be useful in the differential diagnosis of some glomerulopathies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885712     DOI: 10.1093/ajcp/83.4.415

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  25 in total

Review 1.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

2.  Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.

Authors:  George Haddad; Johan M Lorenzen; Hong Ma; Noortje de Haan; Harald Seeger; Christelle Zaghrini; Simone Brandt; Malte Kölling; Urs Wegmann; Bence Kiss; Gábor Pál; Péter Gál; Rudolf P Wüthrich; Manfred Wuhrer; Laurence H Beck; David J Salant; Gérard Lambeau; Andreas D Kistler
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

3.  C1q nephropathy with asymptomatic urine abnormalities.

Authors:  Masashi Nishida; Hidekazu Kawakatsu; Yasuko Okumura; Kenji Hamaoka
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

4.  [Autoantibodies against the complement component C1q in systemic lupus erythematosus].

Authors:  U Antes; H P Heinz; K Hartung; M Loos
Journal:  Klin Wochenschr       Date:  1990-11-09

5.  Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome?

Authors:  Mateja Vintar Spreitzer; Alenka Vizjak; Dušan Ferluga; Rajko B Kenda; Tanja Kersnik Levart
Journal:  Pediatr Nephrol       Date:  2013-07-13       Impact factor: 3.714

6.  C1q nephropathy in children: clinical characteristics and outcome.

Authors:  Vindya N Gunasekara; Neil J Sebire; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

7.  Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

Authors:  S Uwatoko; M Mannik
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

8.  C1q nephropathy in two young sisters.

Authors:  Jameela A Kari; Sawsan M Jalalah
Journal:  Pediatr Nephrol       Date:  2007-10-21       Impact factor: 3.714

9.  A single-center study of C1q nephropathy in children.

Authors:  Isabel Roberti; Noosha Baqi; Shefali Vyas; Dae Un Kim
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

Review 10.  Current status and issues of C1q nephropathy.

Authors:  Akiko Mii; Akira Shimizu; Yukinari Masuda; Emiko Fujita; Kaoru Aki; Masamichi Ishizaki; Shigeru Sato; Adam Griesemer; Yuh Fukuda
Journal:  Clin Exp Nephrol       Date:  2009-04-17       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.